Nolta, Jan - University of California, Davis - Department of Cell Biology and Human Anatomy

研究领域

Dr. Nolta is the Director of the Stem Cell Program at UC Davis School of Medicine, and directs the new Institute for Regenerative Cures. The UC Davis stem cell program has over 145 faculty members collaborating to work toward stem cell-related cures for a spectrum of diseases and injuries. The current research in Dr. Nolta’s laboratory is focused on developing therapies that will use mesenchymal stem cells (MSCs) to deliver factors for treating Huntington’s disease and other disorders and injuries. Her group focuses on “bench to the bedside” research, and she has been involved in numerous clinical trials of gene and cell therapy. She is scientific director of the new Good Manufacturing Practice clean room facility at UC Davis, where stem cells of different types are being isolated or expanded for clinical trials. The basic research in the Nolta laboratory focuses on understanding the dynamics of stem cell migration and attraction to sites of injury. Following intravenous infusion, adult stem cells home to sites of tissue damage. Areas studied are cellular response to hypoxia and chemokines, cell motility, cell-to-cell interactions, and paracrine factors secreted by MSC at the site of injury.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

I. Rosová, D. Link, and J. Nolta. Small Interfering RNA-Mediated Decreases in c-Met Levels Affect the Differentiation Potential of Human Mesenchymal Stem Cells and Reduce Their Capacity for Tissue Repair. Tissue Engineering. 2010 Aug;16(8):2627-39. C Sondergaard, D Hess, D Maxwell, C Weinheimer, I Rosová, M Creer, D Piwnica-Worms, A Kovacs, L Pedersen, and J Nolta. Human UCB Progenitors with High ALDH Activity Improve Vascular Density in Acute Myocardial Infarction. Journal of Translational Medicine. 2010; 8: 24. Capoccia BJ, Robson DL, Levac KD, Maxwell DJ, Hohm SA, Neelamkavil MJ, Bell GI, Xenocostas A, Link DC, Piwnica-Worms D, Nolta JA, Hess DA. Revascularization of ischemic limbs after transplantation of human stem cells with high aldehyde dehydrogenase activity. Blood 2009 21 May, 113 ( 21): 5340-5351. D. Maxwell, J. Bonde, D. Hess, M. Creer, R. Lahey, D. Piwnica-Worms, and J. Nolta. Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human stem cells. Stem Cells. 2008 Feb;26(2):517-24. Rosová I, Dao MA, Capoccia BJ, Link DC, Hess DA, Nolta JA. Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells. Stem Cells. 2008 Aug;26(8):2173-82. D. Hess, T. Craft, L. Wirthlin, W. Eades, M. Creer, M. Sands, J. Nolta. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells. 2008 Mar;26(3):611-20. Zhou P, Hohm S, Capoccia B, Link D, and Nolta JA. Immunodeficient mouse models to study human stem-cell mediated repair of tissue injury. Methods Mol Biol; 2008 430:213-25. T Meyerrose, M Roberts, K Ohlemiller, C Vogler, L Wirthlin, J Nolta, M Sands. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplant model of human disease. Stem Cells. 2008 26:1713-22. G Bauer, M Dao, S Case, P Herrbrich, J Arevalo, T Meyerrose, X Wang, S Csik, D Skelton, D B. Kohn, and J Nolta. In Vivo Biosafety Model to Assess Risk of Adverse Events from Retroviral and Lentiviral Vectors. Mol Ther. 2008 Jul;16(7):1308-15. Meyerrose TE, DeUgarte DA, Hofling A, Herrbrich P, Sands MS, Hedrick MA, and Nolta JA. In vivo Distribution of Adipose-Derived Mesenchymal Stem Cells in Novel Xenotransplant Models. Stem Cells.; 2007 25; 220-227. D Hess, T Meyerrose, L Wirthlin, M Creer, P Herrbrich, T Craft, Nolta J. Functional characterization of highly purified human stem cells isolated based on aldehyde dehydrogenase activity. Blood, 2004 Sept.104:1648-55. Schmidt M, Carbonaro D, Speckmann C, Bohnsack J, Nolta JA, Kohn D, von Kalle C. Clonality Analysis after retroviral–mediated gene transfer to cord blood CD34+ cells of an ADA-deficient SCID infant. Nature Medicine, 2003 Apr1; 9(4); 463-68. Wu G, Nolta JA, Starnes V, and Cramer D. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003 Mar 15; 75(5): 679-685.